9月15日,复星医药控股子公司锦州奥鸿药业开发的创新型小分子 CDK4/6 抑制剂复妥宁®(枸橼酸伏维西利胶囊)新适应症获得国家药品监督管理局批准,用于与芳香化酶抑制剂联合使用作为绝经前、绝经后、围绝经期 HR 阳性、HER2 阴性局部晚期或转移性乳腺癌女性患者的初始内分泌治疗。图片来源:国家药品监督管理局乳腺癌是威胁女性健康的重要癌种。中国国家癌症中心2024年公布的数据显示,2022年中国...
Source Link9月15日,复星医药控股子公司锦州奥鸿药业开发的创新型小分子 CDK4/6 抑制剂复妥宁®(枸橼酸伏维西利胶囊)新适应症获得国家药品监督管理局批准,用于与芳香化酶抑制剂联合使用作为绝经前、绝经后、围绝经期 HR 阳性、HER2 阴性局部晚期或转移性乳腺癌女性患者的初始内分泌治疗。图片来源:国家药品监督管理局乳腺癌是威胁女性健康的重要癌种。中国国家癌症中心2024年公布的数据显示,2022年中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.